ClinicalTrials.gg
TerminatedNCT02882841MOBIDICUpdated Jun 12, 2018

MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients

An interventional study of Biopsies, stool and blood collection in Crohn's Disease, sponsored by Enterome. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-06-12.

Sponsored by Enterome · Not applicable, Interventional, and Diagnostic

How we know

Why this study was terminated
Poor accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
143
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
164th of 528
143 · median 60
Started
2016
with 25 others
No phase
128 of 660
28 open now
Registered
323rd of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 164th largest by enrollment of the 528 interventional ones that give a count, is one of 26 that started in 2016, is one of 128 with no phase, and was the 323rd registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

The study is a multicenter, international descriptive study with a bio-collection in 300 evaluable Crohn's disease patients to be processed after usual biological tests via bioinformatics tools.

At this time, this study has no impact neither on treatment nor on disease diagnostic, these will be based on usual medical practices and is no investigational product associated with the conduct of this study.

Read the detailed description

350 Crohn's disease patients will be included in the study, targeting 300 evaluable patients. An interim analysis will be performed after 50% of the evaluable patients are recruited.

The primary objective is to evaluate the relation between non-invasive biomarkers (host immunological variables and metagenomic analysis in stools) and AIEC detection in biopsies taken during an endoscopy, in order to develop a predictive algorithm of AIEC carriage.

The secondary objectives are:

  • Validation of the AIEC detection algorithm using qPCR technology.
  • Assessment of the correlation between the presence of AIEC and the endoscopic and clinical evaluations of the disease (CDEIS, SES-CD, Harvey-Bradshaw Index and Crohn's Disease Activity Index).
  • Development and validation of a non-invasive qPCR based diagnostic of Mucosal Healing in CD patients.
  • Collection of biological samples associated with all clinical and biological data from CD patients.
03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • AIEC (Adherent and Invasive Escherichia Coli)
  • Mucosal Healing
  • Non-invasive biomarkers
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 75 years of age, inclusive;
  • With a diagnosis of ileal or ileo-colonic Crohn's disease for a minimum of 3 months prior to inclusion;
  • An ileocolonoscopy scheduled prior to study inclusion;
  • Agreeing to participate and to sign an form;
  • Able to perform stool collection, at home, according to protocol;
  • Covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research.

Exclusion criteria

Exclusion Criteria:

  • Colonic Crohn's disease of L2 phenotype based on Montreal classification;
  • Extensive small bowel resection (> 100 cm) or short bowel syndrome
  • Bowel strictures/stenosis contraindicating ilecolonoscopy;
  • Currently with an ostomy or an ileoanal pouch;
  • Currently receiving total parenteral nutrition;
  • Bowel preparation received in the previous 3 months;
  • An increased risk of hemorrhage (patients with anticoagulant/antiplatelet therapy)
  • History of intestinal carcinoma and colorectal cancer;
  • History or presence of alcohol or substance abuse;
  • History of chronic uncontrolled disorders;
  • Current participation in an product trial;
  • Less than 4 weeks since last participation in a clinical trial;
  • Subject inapt or unwilling to participate to the study;
  • Pregnant or breastfeeding mother;
  • Patient under guardianship.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Other
    Single-arm study

    Other: Biopsies, stool and blood collection

Interventions

  • OtherBiopsies, stool and blood collection
06

What researchers measure

Primary outcomes

  1. The primary evaluation criterion is the correlation between the detection of AIEC using a non-invasive stool based algorithm and the detection of AIEC using an ileal biopsy taken during an endoscopy.

    Time frame: 6-12 months between inclusion and analysis

07

Study locations

3 sites
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • Hôpital Saint-Antoine
    Paris, France
  • Guy's and St Thomas' NHS Foundation Trust
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Dec 2017, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2016
First posted
Aug 30, 2016
StartActual
Sep 2016
Primary completionActual
Dec 2017
CompletionActual
Dec 2017
Last update
Jun 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02882841
Lead sponsor
Enterome
Collaborators
Eurofins Optimed
Responsible party
Sponsor
First posted
Aug 30, 2016
Start date
Sep 2016
Primary completion
Dec 2017
Completion
Dec 2017
Last update
Jun 12, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion